Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR

A.R.R.O.W. evaluated the superiority of once-weekly carfilzomib plus dexamethasone (Kd) 20/70 mg/m(2) vs. twice-weekly Kd 20/27 mg/m(2) based on progression-free survival (PFS) in relapsed and/or refractory multiple myeloma patients. Forty Japanese patients (once-weekly arm, n = 26; twice-weekly arm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Hematol
Main Authors: Takezako, Naoki, Shibayama, Hirohiko, Handa, Hiroshi, Hagiwara, Shotaro, Ozaki, Shuji, Suzuki, Kenshi, Kosugi, Hiroshi, Ri, Masaki, Sugiura, Isamu, Choi, Ilseung, Miyamoto, Toshihiro, Iida, Shinsuke
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Singapore 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7547551/
https://ncbi.nlm.nih.gov/pubmed/33037990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12185-020-03013-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados